Abstract��
OBJECTIVE To examine the characteristics of the evidence-based clinical literatures regarding the Chinese patent medicines on the National Essential Medicine List of China (2009 Edition) so as to lay a foundation for the establishment of an evidence-based pharmaceutical review system for the Chinese patent medicines oriented at treating TCM-syndromes. METHODS The evidence-based literatures on Chinese patent medicines were categorized�� and their characteristics were analyzed concerning the distribution of the literatures according to the five levels of evidence�� the concentration of the diseases under treatment�� and chronological changes; in accordance with the Drug Registration Regulation�� the differences among these literatures were explored. RESULTS With regard to the literatures on some Chinese patent medicines�� there were a large proportion of randomized controlled trials (RCTs)�� with a rapid increase in the number of the literatures in recent years and a clear focus on certain diseases. By contrast�� some other Chinese patent medicines had a high proportion of before-after studies and empirical introductions as well as a low concentration of diseases under treatment. CONCLUSION The Chinese patent medicines can be divided into two categories�� namely�� the modern branch and the traditional branch. While the disease-oriented evidence-based review system can be applied to the evaluation of the literatures on some patent medicines in the modern branch�� it does not fit the traditional branch. Therefore�� in order to reflect the characteristics of the Chinese patent medicines�� a TCM-syndrome-oriented evidence-based review system has to be established.
PU Run,
GENG Xiang-Nan,
XIN Xiao-Xiong etc
.Research into Evidence-based Literatures on the Chinese Patent Medicines on the National Essential Medicine List[J] Chinese Pharmaceutical Journal, 2012,V47(14): 1164-1167
��
[1]
WANG J W. Evidence-based medicine in China[J]. Lancet�� 2010�� 375(9714)�� 532-533.
[2]
NOVIASKY J A. Evidence-based pharmacy versus opinion on generic product selection of warfarin[J]. Am J Health-Syst Pharm�� 1999�� 56(1)��2246-2247.
[3]
TANG J B. Information on evidence-based medicine and pharmacy. [J]. Chin Pharm J (�й�ҩѧ��־)�� 1998��33(10)�� 624-625.
[4]
em>National Essential Medicine List for Primary Care Section�����һ���ҩ��Ŀ¼��[M].Beijing�� China Legal Publishing House�� 2009��19-25.
[5]
National Health and Medical Research Council. How to Use the Evidence Assessment and Application of Scientific Evidence[M]. Canberra�� Commonwealth of Australia�� 2000.
2012, Vol. 47 
